214 related articles for article (PubMed ID: 22593619)
21. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
22. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
23. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
[TBL] [Abstract][Full Text] [Related]
24. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
26. Enhanced IL-10 production by CD4+ T cells primed in IL-15Rα-deficient mice.
Chow KP; Lee JM; Qiu JT; Liao SK; Lin SC; Hsu SL; Wu NN; Lin YF; Wu TS
Eur J Immunol; 2011 Nov; 41(11):3146-56. PubMed ID: 21874651
[TBL] [Abstract][Full Text] [Related]
27. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Steel JC; Ramlogan CA; Yu P; Sakai Y; Forni G; Waldmann TA; Morris JC
Cancer Res; 2010 Feb; 70(3):1072-81. PubMed ID: 20086176
[TBL] [Abstract][Full Text] [Related]
29. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
[TBL] [Abstract][Full Text] [Related]
30. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
Stoklasek TA; Schluns KS; Lefrançois L
J Immunol; 2006 Nov; 177(9):6072-80. PubMed ID: 17056533
[TBL] [Abstract][Full Text] [Related]
31. Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.
Hong E; Usiskin IM; Bergamaschi C; Hanlon DJ; Edelson RL; Justesen S; Pavlakis GN; Flavell RA; Fahmy TM
J Biol Chem; 2016 Apr; 291(17):8931-50. PubMed ID: 26719339
[TBL] [Abstract][Full Text] [Related]
32. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Jiang Q; Weiss JM; Back T; Chan T; Ortaldo JR; Guichard S; Wiltrout RH
Cancer Res; 2011 Jun; 71(12):4074-84. PubMed ID: 21540234
[TBL] [Abstract][Full Text] [Related]
33. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation.
Lodolce JP; Burkett PR; Boone DL; Chien M; Ma A
J Exp Med; 2001 Oct; 194(8):1187-94. PubMed ID: 11602647
[TBL] [Abstract][Full Text] [Related]
34. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
35. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.
Sato N; Sabzevari H; Fu S; Ju W; Petrus MN; Bamford RN; Waldmann TA; Tagaya Y
Blood; 2011 Apr; 117(15):4032-40. PubMed ID: 21304101
[TBL] [Abstract][Full Text] [Related]
36. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
[TBL] [Abstract][Full Text] [Related]
37. Selective reduction of post-selection CD8 thymocyte proliferation in IL-15Rα deficient mice.
Chow KP; Qiu JT; Lee JM; Hsu SL; Yang SC; Wu NN; Huang W; Wu TS
PLoS One; 2012; 7(3):e33152. PubMed ID: 22448237
[TBL] [Abstract][Full Text] [Related]
38. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
39. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
40. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
